{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AR-13324+Ophthalmic+Solution+Placebo",
    "query": {
      "intervention": "AR-13324 Ophthalmic Solution Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AR-13324+Ophthalmic+Solution+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T02:16:36.710Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05660447",
      "title": "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Rhegmatogenous Retinal Detachment",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]",
          "type": "DRUG"
        },
        {
          "name": "Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-02-06",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-30",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660447"
    },
    {
      "nct_id": "NCT06865144",
      "title": "Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma or Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Netarsudil ophthalmic solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "East Coast Institute for Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-06-27",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06865144"
    },
    {
      "nct_id": "NCT03248037",
      "title": "Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fuchs' Endothelial Dystrophy",
        "Bullous Keratopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornea Research Foundation of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2017-09-05",
      "completion_date": "2019-07-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-12",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248037"
    },
    {
      "nct_id": "NCT01528787",
      "title": "Study of AR-13324 in Patients With Elevated Intraocular Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.01%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 85,
      "start_date": "2012-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2018-04-18",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 11,
      "location_summary": "Newport Beach, California • Fairfield, Connecticut • Roswell, Georgia + 8 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528787"
    },
    {
      "nct_id": "NCT03310580",
      "title": "Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma or Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.04%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-11-15",
      "completion_date": "2018-10-25",
      "has_results": true,
      "last_update_posted_date": "2019-12-23",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 40,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Azusa, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03310580"
    },
    {
      "nct_id": "NCT03971357",
      "title": "Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Fuchs' Endothelial Dystrophy"
      ],
      "interventions": [
        {
          "name": "Netarsudil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Price Vision Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2019-07-22",
      "completion_date": "2021-08-26",
      "has_results": true,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03971357"
    },
    {
      "nct_id": "NCT02207491",
      "title": "Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 411,
      "start_date": "2014-07",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-13",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207491"
    },
    {
      "nct_id": "NCT02874846",
      "title": "Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil ophthalmic solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Netarsudil Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-07",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02874846"
    },
    {
      "nct_id": "NCT02246764",
      "title": "Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "19 Years to 99 Years"
      },
      "enrollment_count": 93,
      "start_date": "2014-09",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246764"
    },
    {
      "nct_id": "NCT02207621",
      "title": "Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "AR-13324 Ophthalmic Solution 0.02%",
          "type": "DRUG"
        },
        {
          "name": "Timolol maleate Ophthalmic Solution 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "AR-13324 Ophthalmic Solution 0.02% BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aerie Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 756,
      "start_date": "2014-07",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-06",
      "last_synced_at": "2026-10-01T02:16:36.710Z",
      "location_count": 1,
      "location_summary": "Bedminster, New Jersey",
      "locations": [
        {
          "city": "Bedminster",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02207621"
    }
  ]
}